BASKING RIDGE, N.J., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”),
a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select
therapeutic product pipeline, has licensed exclusive global rights to its cell-derived dermatological technology for topical skin
applications to AiVita Biomedical, Inc. (“AiVita”). This transaction supports the Company’s strategy to monetize non-core
assets.
AiVita is a biotechnology company created to advance commercial and clinical stage programs utilizing curative and regenerative
medicines. The company was founded in 2016 by Dr. Hans Keirstead, Caladrius’ former Chief Science Officer, and expects to
manufacture and distribute a cosmetic skincare product based on the licensed technology for commercial sale beginning in the second
quarter of 2016 through ALPHAEON Corporation (“ALPHAEON”). ALPHAEON, a social commerce company in lifestyle healthcare, has an
established board-certified physician community of more than 10,000 members coupled with e-commerce capabilities. Caladrius will
receive royalties on net sales.
“Licensing this dermatological technology to AiVita is yet another step forward in streamlining our strategic focus while
monetizing non-core assets through royalty- and/or other milestone-driven transactions. In this case, the technology fits neither
the type nor the scope of manufacturing that is the basis of PCT’s business,” said David J. Mazzo, Ph.D., Chief Executive Officer
of Caladrius. “We look forward to ALPHAEON’s launch of this product and to sharing in its economic success.”
About AiVita Biomedical
AiVita Biomedical is advancing commercial and clinical-stage programs utilizing curative and regenerative medicines. Built upon
expertise in stem cell growth and directed, high- purity differentiation, AiVita Biomedical has engineered safe, efficient and
economical manufacturing systems to support the development and commercialization of curative and regenerative medicines. For more
information, visit www.aivitabiomedical.com.
About ALPHAEON Corporation
ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by leveraging the power of
its professional network of physician specialists to drive lifestyle healthcare advancements, and improve patient experiences and
outcomes in the wellness, beauty and performance sectors. For more information, please visit www.alphaeon.com.
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its wholly-owned subsidiary, PCT, is a leading development and manufacturing partner to the
cell therapy industry. Caladrius works with its clients to overcome the fundamental challenges of cell therapy manufacturing
by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and
automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support.
Around this core expertise, Caladrius strategically develops product candidates, which currently include an innovative therapy for
type 1 diabetes based on a proprietary platform technology for immunomodulation, and holds intellectual property around other cell
therapy platform technologies. For more information, visit www.caladrius.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are
forward-looking statements, including statements regarding our expected revenues and capital expenditures, personnel reductions, as
well as the potential of CLBS03 in the treatment of recent-onset type 1 diabetes and the expected cost savings associated with the
termination of the CLBS20 study. The Company’s actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report
on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2015, and in the Company’s other periodic
filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research
developments and market acceptance, which are outside of its control.
CONTACTS: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: afields@lhai.com Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: epowers@caladrius.com
